✦ LIBER ✦

ChemInform Abstract: Discovery of INCB3344 (I), a Potent, Selective and Orally Bioavailable Antagonist of Human and Murine CCR2.

✍ Scribed by Chu-Biao Xue; et al. et al.

Publisher: John Wiley and Sons
Year: 2011
Weight: 21 KB
Volume: 42
Category: Article
ISSN: 0931-7597
DOI: 10.1002/chin.201115116

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Discovery of Potent, Orally Bioavailable

Discovery of Potent, Orally Bioavailable Small-Molecule Inhibitors of the Human CCR2 Receptor

✍ Julien Doyon; Erwin Coesemans; Staf Boeckx; Mieke Buntinx; Bart Hermans; Jean P. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 293 KB 👁 1 views

Antagonists of Human CCR5 Receptor Conta

Antagonists of Human CCR5 Receptor Containing 4-(Pyrazolyl)piperidine Side Chains. Part 2. Discovery of Potent Selective, and Orally Bioavailable Compounds.

✍ Dong-Ming Shen; et al. et al. 📂 Article 📅 2004 🏛 John Wiley and Sons ⚖ 65 KB 👁 2 views

## Abstract For Abstract see ChemInform Abstract in Full Text.

ChemInform Abstract: Discovery of Potent

ChemInform Abstract: Discovery of Potent and Selective Phenylalanine Derived CCR3 Receptor Antagonists. Part 2.

✍ Dashyant Dhanak; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 26 KB 👁 1 views

ChemInform Abstract: The Discovery of YM

ChemInform Abstract: The Discovery of YM-60828: A Potent, Selective and Orally-Bioavailable Factor Xa Inhibitor.

✍ Fukushi Hirayama; et al. et al. 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 25 KB 👁 1 views

Discovery of SB-705498: A Potent, Select

Discovery of SB-705498: A Potent, Selective and Orally Bioavailable TRPV1 Antagonist Suitable for Clinical Development.

✍ Harshad K. Rami; et al. et al. 📂 Article 📅 2006 🏛 John Wiley and Sons ⚖ 10 KB

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

Discovery and Synthesis of a Potent, Sel

Discovery and Synthesis of a Potent, Selective and Orally Bioavailable EP4 Receptor Agonist

✍ Robert N. Young; et al. et al. 📂 Article 📅 2005 🏛 John Wiley and Sons ⚖ 9 KB 👁 2 views